bromhexine
Bromhexine is a mucolytic drug used in the treatment of respiratory disorders associated with viscid or excessive mucus. It was developed in the research laboratory of Boehringer Ingelheim in the late 1950s as an active ingredient for pharmaceutical use, patented in 1961, introduced in 1963 under the trademark of Bisolvon® and came into medical use in 1966. — Wikipedia
Clinical trial activity
9 trials · 21 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 2011 (NCT01423721)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Unknown
Bromhexine is a secretolytic agent, increasing the production of serous mucus in the respiratory tract and makes the phlegm thinner and less viscous. This contributes to a secretomotoric effect by helping the cilia transport the phlegm out of the lungs. Its mechanism of action is complex and remains incompletely explored.
Chemistry & pharmacology
SMILES
CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1- Mol. weight
- 376.14 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL253376 ↗
- WikipediaBromhexine ↗
- ChEMBLCHEMBL1319139 ↗
Also known as
- 3,5-dibromo-n(alpha)-cyclohexyl-n(alpha)-methyltoluene-alpha-2-diamine
- 3,5-dibromo-n(alpha)-cyclohexyl-n(alpha)-methyltoluene-alpha-2-diamine
- bisolvon
- bisolvon
- brombenzonium
- brombenzonium
- bromexina
- bromexina
- bromexine
- bromhexina
- bromhexina
- bromhexine
- bromhexine
- bromhexine
- bromhexine
- bromhexine
- bromhexine
- bromhexine
- bromhexine hcl
- bromhexine hcl
- bromhexine hcl
- bromhexine hydrochloride
- bromhexine hydrochloride
- bromhexine hydrochloride
- bromhexine monohydrochloride
- bromhexinum
- bromhexinum
- bromihexine hydrochloride
- fluibron
- fluibron
- na-274
- na-274
- n-cyclohexyl-n-methyl-(2-amino-3,5-dibrombenzyl)amine
- n-cyclohexyl-n-methyl-(2-amino-3,5-dibrombenzyl)amine
- tauglicolo
- tauglicolo
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04672707 | Phase 1 | Dec 12, 2021 | WanBangDe Pharmaceutical Group Co.,Ltd., Wenzhou Medical University |
| NCT05087381 | Phase 4 | Oct 1, 2021 | Chulalongkorn University, Government of Thailand, Mae Fah Luang University Hospital, Mahidol University, Rajavithi Hospital, Bangkok, University of Queensland, University of Western Australia, Washington University in St. Louis, Yamagata Prefectural Central Hospital |
| NCT04928495 | Phase 3 | Jul 15, 2021 | Federal University of Ceara, Government of Brazil, Leonardo da Vinci Hospital - HLV, São José Hospital for Infectious Diseases - HSJ, Universidade Estadual Paulista Júlio de Mesquita Filho |
| NCT04424134 | Phase 3 | May 16, 2020 | Moscow State University |
| NCT04405999 | Phase 4 | May 14, 2020 | Government of Russia |
| NCT04355026 | Phase 4 | Apr 10, 2020 | General and Teaching Hospital Celje |
| NCT04340349 | Early Phase 1 (Phase 1) | Apr 10, 2020 | Instituto Nacional de Rehabilitacion |
| NCT04273763 | N/A | Feb 16, 2020 | WanBangDe Pharmaceutical Group Co.,Ltd., Wenzhou Medical University |
| NCT01423721 | Phase 1 | Aug 1, 2011 | Boehringer Ingelheim |